<DOC>
	<DOCNO>NCT01008332</DOCNO>
	<brief_summary>The prevalence allergic sensitisation House Dust Mite ( HDM ) vary region region depend regional prevalence HDM . In third National Health Nutrition Examination Surveys , 54.3 % US population positive test responses one allergen , prevalence HDM 27.5 % . Like many allergen , exposure HDMA sensitise patient associate poor lung function , great medication requirement asthma symptom well chronic rhinosinusitis symptom . ToleroMune HDM novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment Houst Dust Mite allergy . The purpose present study evaluate safety tolerability multiple ascending dos ToleroMune HDM subject subject document history allergic rhinoconjunctivitis exposure house dust mite . The efficacy ToleroMune HDM also explore subject use Late Phase Skin Response , Early Phase Skin Response Conjunctival Provocation Test .</brief_summary>
	<brief_title>Safety ToleroMune House Dust Mite ( HDM ) Treat House Dust Mite Allergy HDM Allergic Subjects With Rhinoconjunctivitis</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled study evaluate safety tolerability escalate multiple dos ToleroMune HDM subject document history allergic rhinoconjunctivitis exposure house dust mite . The efficacy ToleroMune HDM also explore subject use LPSR , EPSR , CPT level HDM specific IgE . A single centre initiate first , second centre include backup , need , enable recruitment number meet . The study consist 3 study period . In Period 1 , Screening perform maximum 8 week randomisation may consist one two visit clinic , Investigator 's discretion . Baseline Challenge consist single visit 1 4 week randomisation . Period 2 ( Treatment Period ) consist 4 visit ( Visits 3A-3D ) four week apart ( 28±2 day ) . Subjects comply inclusion/exclusion criterion assign one 5 dose group . The first dose group receive 4 administration ToleroMune HDM . Successive dose group increase dos give 4 administration ToleroMune HDM , provide first administration previous dose safe well tolerate . In Period 3 , Post-treatment Challenge take place 18-22 week first administration Treatment Period . Assessments perform identical Baseline Challenge . Follow-up conduct 3-10 day PTC .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Male female , age 1865 year Miniumum 1 year history rhinoconjunctivitis exposure HDM Positive skin prick test whole Der p allergen LPSR whole Der p allergen 810 hour intradermal injection great 35mm diameter response Positive CPT whole Der p allergen score ≥4 Subjects history asthma Subjects FEV1 &lt; 80 % predicted Subjects Der f Der p specific IgE &gt; 100 kU/L Subjects acute phase skin response whole Der p whole Der f allergen mean wheal diameter &gt; 50 mm Subjects score &gt; 1 redness conjunctiva water itchiness eye administration CPT Treatment betablockers , alphaadrenoreceptor blocker , tranquillizer psychoactive drug History significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>House Dust Mite Allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Toleromune HDM</keyword>
</DOC>